


(S)-V-0219

Cat. No.:	HY-143312C
CAS No.:	3031984-78-5
Molecular Formula:	C ₂₀ H ₂₅ F ₃ N ₄ O ₂
Molecular Weight:	410.43
Target:	GLP Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice ^[1] .
IC₅₀ & Target	GLP-1R ^[1]
In Vitro	(S)-V-0219 ((S)-9) (0.1 nM) potentiates calcium fluxes in HEK cells stably expressing hGLP-1R ^[1] . (S)-V-0219 (0.1 nM) potentiates insulin secretion stimulated by GLP-1 in the stable human pancreatic cell line EndoC-βH1 under high glucose concentration ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	(S)-V-0219 ((S)-9) (0.04-0.2 mg/kg; i.p.) improves glucose handling after injection of 2 g/kg glucose in normal male Wistar rats ^[1] . (S)-V-0219 (0.4 mg/kg; i.g.) is orally active in fatty diabetic Zucker rats ^[1] . (S)-V-0219 (0.1-5 μg/kg in 5 μL; i.c.v.) decreases feeding in 12-h fasted male Wistar rats ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Decara JM, et, al. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabetesity". J Med Chem. 2022 Apr 14;65(7):5449-5461.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA